（三）实用指导
在本节中，程序步骤需要产生与报告的有效性结构域评估要素相对应的结果。
为了完成一个或多个有效性结构域系统评估，需要执行一个或多个系统评估，还要回答每个选定的问题。有预先确定的步骤用于编写系统评估（2009年CRD医疗卫生评估指导；Higgins等，2011；卫生技术评估核心模型手册，2012；2013年HTA快速药物模型；Moher等，2009），如表33至表42所示。
表33 从卫生技术评估核心模型评估要素中选择主题和问题
表34 研究问题的定义
表35 确定研究的纳入标准定义
（续表）
（续表）
表36 系统的证据搜寻
表37 选择研究
表38 数据提取
表39 方法学质量评估
表40 数据综合
表41 证据质量分级
表42 报告
参考文献
① Assessment Element for Diagnostic Technologies 2012.EUnet HTA 2012.Available at https：／／meka.thl.fi／htacore／View Handbook.aspx？full＝1&id＝6；last access May 10th 2013
② Assessment Element for Screening Technologies 2012.EUnet HTA 2012.Available at https：／／meka.thl.fi／htacore／View Handbook.aspx？full＝1&id＝6；last access May 10th 2013
③Assessment Element for Medical and Surgical Interventions 2012.EUnet HTA 2012.Available at https：／／meka.thl.fi／htacore／View Handbook.aspx？full＝1&id＝6；last access May 10th 2013
④Balshem H，Helfand M，Schünemann HJ，Oxman AD，Kunz R，Brozek J，Vist GE，Falck-Ytter Y，Meerpohl J，Norris S，Guyatt GH.GRADE guidelines：3.Rating the quality of evidence.J Clin Epidemiol 2011；64：401-6.
⑤ Bossuyt PM，Irwig L，Craig J，Glasziou P.Comparative accuracy：assessing new tests against existing diagnostic pathways.BMJ 2006 6；332：1089-92.
⑥Bossuyt PM，Reitsma JB，Bruns DE，Gatsonis CA，Glasziou PP，Irwig LM，Lijmer JG，Moher D，Rennie D，de Vet HC；Standards for Reporting of Diagnostic Accuracy.Towards complete and accurate reporting of studies of diagnostic accuracy：the STARD initiative.BMJ 2003；326：41-4.
⑦Centre for Reviews and Dissemination.Systematic Reviews：CRD's Guidance for Undertaking Reviews in Healthcare.Jan 2009.Available from www.york.ac.uk／inst／crd／index＿guidance.htm；last access May 10th 2013.
⑧Diagnostic Test Accuracy Working Group.Handbook for DTA Reviews.2011.Available from http：／／srdta.cochrane.org／handbook-dta-reviews；last access May 10th 695 2013.
⑨EUnet HTA.Endpoints used for REA of pharmaceuticals：composite endpoints.February 2013.
⑩EUnet HTA.Comparators and comparisons—Direct and Indirect Comparisons.February 2013
[11] EUnet HTA.Health-Related Quality Of Life and Utility Measures.February 2013
[12] EUnet HTA.Levels of evidence：Internal validity（of randomized controlled trials）.February 2013
[13] EUnet HTA.Endpoints used for REA of pharmaceuticals—Safety.February 2013
[14] EUnet HTA.Endpoints used in REA of pharmaceuticals：surrogate endpoints.February 2013
[15] EUnet HTA.Levels of evidence：applicability of evidence in the context of a relative effectiveness assessment of pharmaceuticals February 2013
[16] EUnet HTA.Comparators&comparisons：criteria for the choice of the most appropriate comparator（s）February 2013
[17] EUnet HTA.Endpoints used for REA of pharmaceuticals—Clinical endpoints February 2013 to be updated with new references when available
[18] Guyatt G，Oxman AD，Akl EA，Kunz R，Vist G，Brozek J，Norris S，Falck-Ytter Y，Glasziou P，DeBeer H，Jaeschke R，Rind D，Meerpohl J，Dahm P，Schünemann HJ.GRADE guidelines：1.Introduction-GRADE evidence profiles and summary of findings tables.J Clin Epidemiol 2011a；64：383-94.
[19] Guyatt GH，Oxman AD，Kunz R，Brozek J，Alonso-Coello P，Rind D，Devereaux PJ，Montori VM，Freyschuss B，Vist G，Jaeschke R，Williams JW Jr，Murad MH，Sinclair D，Falck-Ytter Y，Meerpohl J，Whittington C，Thorlund K，Andrews J，Schünemann HJ.GRADE guidelines 6.Rating the quality of evidence-imprecision.J Clin Epidemiol 2011d；64：1283-93.
[20] Guyatt GH，Oxman AD，Kunz R，Woodcock J，Brozek J，Helfand M，Alonso-Coello P，Glasziou P，Jaeschke R，Akl EA，Norris S，Vist G，Dahm P，Shukla VK，Higgins J，Falck-Ytter Y，Schünemann HJ；GRADE Working Group.GRADE guidelines：7.Rating the quality of evidenceinconsistency.J Clin Epidemiol 2011e；64：1294-302.
[21] Guyatt GH，Oxman AD，Kunz R，Woodcock J，Brozek J，Helfand M，Alonso-Coello P，Falck-Ytter Y，Jaeschke R，Vist G，Akl EA，Post PN，Norris S，Meerpohl J，Shukla VK，Nasser M，Schünemann HJ；GRADE Working Group.GRADE guidelines：8.Rating the quality of evidenceindirectness.J Clin Epidemiol 2011f；64：1303-10.
[22] Guyatt GH，Oxman AD，Montori V，Vist G，Kunz R，Brozek J，Alonso-Coello P，Djulbegovic B，Atkins D，Falck-Ytter Y，Williams JW Jr，Meerpohl J，Norris SL，Akl EA，Schünemann HJ.GRADE guidelines：Rating the quality of evidence-publication bias.J Clin Epidemiol 2011c；64：1277-82.
[23] Guyatt GH，Oxman AD，Santesso N，Helfand M，Vist G，Kunz R，Brozek J，Norris S，Meerpohl J，Djulbegovic B，Alonso-Coello P，Post PN，Busse JW，Glasziou P，Christensen R，Schünemann HJ.GRADE guidelines：12.Preparing summary of findings tables-binary outcomes.J Clin Epidemiol 2013；66：158-72.
[24] Guyatt GH，Oxman AD，Sultan S，Glasziou P，Akl EA，Alonso-Coello P，Atkins D，Kunz R，Brozek J，Montori V，Jaeschke R，Rind D，Dahm P，Meerpohl J，Vist G，Berliner E，Norris S，Falck-Ytter Y，Murad MH，Schünemann HJ；GRADE Working Group.GRADE guidelines：9.Rating up the quality of evidence.J Clin Epidemiol 2011g；64：1311- 6
[25] Guyatt GH，Oxman AD，Vist G，Kunz R，Brozek J，Alonso-Coello P，Montori V，Akl EA，Djulbegovic B，Falck-Ytter Y，Norris SL，Williams JW Jr，Atkins D，Meerpohl J，Schünemann HJ.GRADE guidelines：4.Rating the quality of evidence—study limitations（risk of bias）.J Clin Epidemiol 2011b；64：407-15
[26] Hayden JA，van der Windt DA，Cartwright JL，CôtéP，Bombardier C.Assessing bias in studies of prognostic factors.Ann Intern Med 2013；158：280- 6.
[27] Higgins JPT，Green S （editors）.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0［updated March 2011］.The Cochrane Collaboration，2011.Available from www.cochrane-handbook.org.Chapter 5：Defining the review question and developing criteria for including studies；last access May 10th 2013.
[28] HTA Core Model Handbook 2012.EUnet HTA 2012.Available at https：／／meka.thl.fi／htacore／View Handbook.aspx；last access May 10th 2013.
[29] Jefferson T，Vicari N，Frønsdal KB （eds）.Abdominal Aorta Aneurysm Screening.EUnet HTA 2013a.
[30] Jefferson T，Vicari N，Raatz H （eds）.Prognostic tests for breast cancer recurrence（uPA／PAI-1［FEMTELLE］，MammaPrint，Oncotype DX）.EUnet HTA 2013b.
[31] Methods Guide for Medical Test Reviews.AHRQ Publication No.12-EC017.Rockville，MD：Agency for Healthcare Research and Quality；June 2012.Available from www.effectivehealthcare.ahrq.gov／reports／final.cfm；last access May 10th 2013.
[32] Model for Rapid REA of pharmaceuticals.EUnet HTA 2013.Available at http：／／www.eunethta.eu／outputs／new-application-hta-core-model-hta-core-model-rapid-relative？ effectiveness-assessmentpharma；last access May 10th 2013.
[33] Moher D，Liberati A，Tetzlaff J，Altman DG，The PRISMA Group.Preferred Reporting Items for Systematic Reviews and Meta-Analyses： The PRISMA Statement.PLoS Medicine 2009；6：e1000097.
[34] Schünemann HJ，Oxman AD，Brozek J，Glasziou P，Jaeschke R，Vist GE，Williams JW Jr，Kunz R，Craig J，Montori VM，Bossuyt P，Guyatt GH；GRADE Working Group.BMJ 2008；336：1106-10.
[35] Shea BJ，Bouter LM，Peterson J，Boers M，Andersson N，Ortiz Z，Ramsay T，Bai A，Shukla VK，Grimshaw JM.External Validation of a Measurement Tool to Assess Systematic Reviews（AMSTAR）.PLoS 2007；2（12）：e1350.Available also from http：／／www.amstar.ca／；last access May 10th 2013.
[36] Wells GA，Shea B，O'Connell D，Peterson J，Welch V，Losos M，Tugwell P.The Newcastle-Ottawa Scale（NOS）for assessing the quality of nonrandomised studies in meta-analyses.Available from www.ohri.ca／programs／clinical＿epidemiology／oxford.htm；last access May 10th 2013.
[37] Whiting PF，Rutjes AWS，Westwood ME，Mallett S，Deeks JJ，Reitsma JB，Leeflang MM，Sterne JAC，and Bossuyt PMM.QUADAS-2：A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies.Ann Intern Med 155（8）：529-536，2011.Available also from http：／／www.bris.ac.uk／quadas／；last access May 10th 2013.
[38] EUnet HTA GL Meta-analysis of diagnostic test accuracy studies（2014）